Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA.
Kantrowitz JT, et al. Among authors: potter wz.
Neuropsychopharmacology. 2020 Oct;45(11):1842-1850. doi: 10.1038/s41386-020-0706-z. Epub 2020 May 13.
Neuropsychopharmacology. 2020.
PMID: 32403118
Free PMC article.
Clinical Trial.